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1. Introduction 
Heart failure is the final stage of most of cardiac diseases. It is a complex syndrome in which 
the patients should have the following features: symptoms of heart failure, typically shortness 
of breath at rest or during exertion, and/or fatigue; signs of fluid retention such as pulmonary 
congestion or ankle swelling; and objective evidence of an abnormality of the structure or 
function of the heart at rest. This progressive syndrome as a high incidence and prevalence 
and poor prognosis: four-year mortality is around 50% with 40% of the patients admitted to 
hospital dying or readmitted within a year (European Society of Cardiology, 2008). With 
ageing, many patients will develop chronic heart failure, which, because of its symptoms, 
patient’s awareness of their risk of dying, and the effects of therapy, together with frequent 
hospitalizations, has considerable impact on patient’s health-related quality of life. 
In the actual field of management, implantable devices have an important role for select 
patients. According to the European Society of Cardiology guidelines for the diagnosis and 
treatment of acute and chronic heart failure (2008), cardiac resynchronization therapy with 
defibrillator function is recommended to reduce morbidity and mortality in patients in New 
York Heart Association III-IV class who are symptomatic despite optimal medical therapy, 
and who have a reduced ejection fraction (left ventricular ejection fraction ≤35%) and QRS 
prolongation (QRS width ≥120 ms) and implantable cardioverter-defibrillator is 
recommended for primary prevention of sudden death to reduce mortality in patients with 
ventricular dysfunction due to prior myocardial infarction or non-ischemic cardiomyopathy 
with a left ventricular ejection fraction ≤35% in New York Heart Association functional class 
II or III, receiving optimal medical therapy, and who have reasonable expectation of 
survival with good functional status for more than one year. 
The effect of these therapies in the quality of life in general and regarding the type of 
therapeutic response in particular is a field under investigation. 
The aim of this study was to evaluate the impact of cardiac resynchronization therapy and 
implantable cardioverter-defibrillator in the quality of life of patients with chronic heart failure 
refractory to optimal pharmacological therapy in the first six months after device implantation.  
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2. Method 
2.1 Participants 
From ninety-six patients with chronic heart failure refractory to optimal pharmacological 
therapy in consecutive sequential analysis, fifty-two underwent implantation of cardiac 
resynchronization therapy system combined with implantable cardioverter-defibrillator and 
forty-four systems with implantable cardioverter-defibrillator alone for primary prevention 
of sudden death. 
In the cardiac resynchronization therapy group, age was 64,2±8,9 (37-78) years with 35 
males and 17 females, left ventricular ejection fraction was 24,6±5,4 (11-35)% and 94% in 
class III of the New York Heart Association classification. The etiology was mostly 
idiopathic (46,2%) or ischemic (34,6%).   
In the implantable cardioverter-defibrillator group, age was 61,1±12,6 (25-83) years with 38 
males and 6 females, left ventricular ejection fraction was 26,1±5,4 (15-37)% and 82,9% in 
class II of New York Heart Association classification. The etiology was mostly ischemic 
(75%) (Figure 1). 
 
 Characteristics 
Cardiac 
Resyncrhronization 
Therapy 
Implantable 
Cardioverter-
Defibrillator 
    
Age M 64,2 61,1 
 DP 8,9 12,6 
    
Gender Male 67,3% 86,4% 
 Female 32,7% 13,6% 
    
Left Ventricular 
Ejection Fraction  
M 24,6% 26,1% 
 DP 5,4 5,4 
    
New York Heart 
Association 
Classification 
Class I 0% 0% 
 Class II 4,0% 82,9% 
 Class III 94% 17,1% 
 Class IV 2% 0% 
    
Etiology of Chronic 
Heart Failure 
Ischemic 
Hypertensive 
34,6% 75,0% 
7,7% 0% 
 Valvular 7,7% 2,3% 
 Idiopathic 46,2% 20,5% 
 Other 3,8% 2,3% 
Fig. 1. Population Characteristics 
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2.2 Instruments and procedure 
Patients were assessed at admission, immediately before the intervention, and in the 
outpatient clinic within 6 months. We considered functionality by the New York Heart 
Association classification, left ventricular ejection fraction and the quality of life Kansas City 
Cardiomyophathy Questionnaire. 
The Kansas City Cardiomyopathy Questionnaire (Green et al., 2000) validated for the 
portuguese population (Nave-Leal et al., 2010) is composed of twenty three items divided 
into five domains: physical limitation, symptoms, quality of life, self-efficacy and social 
interference. The physical limitation domain measures the extent to which congestive 
heart failure symptoms have limited some of the patient’s physical activities over the 
previous two weeks. The symptom domain assesses the number of times that congestive 
heart failure symptoms such as fatigue, dyspnea or limb edema have occurred in the 
previous two weeks and whether there have been changes in symptoms during the same 
period. The self-efficacy domain measures the patient’s knowledge of how to avoid 
worsening of symptoms and of what to do if this occurs. The quality of life domain 
evaluates patients’ perception of their enjoyment of life and of their sense of 
discouragement due to their heart failure, while the social interference domain assesses 
how congestive heart failure affects the patient’s lifestyle. To facilitate interpretability, 
two summary scores were developed: the first, the functional status score, combines the 
physical limitation and symptom domains, and the second, the clinical summary score, 
combines the functional status score with the quality of life and social interference 
domains (Figure 2).  
 
 
 
Fig. 2. Domains and Summaries of the Kansas City Cardiomyopathy Questionnaire 
Kansas City Cardiomyopathy Questionnaire 
(Twenty three items) 
Five Domains 
Physical Limitation 
Symptoms 
Self-efficacy 
 Quality of Life 
Social Interference 
Two Summaries 
Functional Status 
(physical limitation+symptoms) 
Clinical Summary (functional 
status+quality of life+social 
interference)
(scores: 0 a 100%) 
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His psychometrics proprieties shows that it’s a good instrument regarding fidelity,  validity, 
sensitive to clinical change and specific to measure quality of life in a population with 
chronic heart failure. 
The New York Heart Association classification (The Criteria Committee of the New York 
Heart Association, 1994 cited by European Society of Cardiology, 2008) measures the 
functional capacity based on the severity of symptoms and limitation of physical activity 
and is the most widely used measure to assess functionality of cardiac patients. Class I is 
defined as the absence of limitations on the exercise usually does not cause fatigue, 
dyspnoea or palpitations; Class II is characterized by a slight limitation of physical activity, 
being comfortable at rest but ordinary physical activity causes fatigue, palpitations or 
dyspnea; Class III is defined by a marked limitation of physical activity, being comfortable 
at rest but in a less intense activity that usually causes symptoms of heart failure, class IV is 
characterized by an inability to perform any physical activity without discomfort, where the 
symptoms of heart failure are present. 
The left ventricular ejection fraction calculated by echocardiography in a percentage below 
35% is indicative of poor prognosis. 
3. Results 
During the first six months of follow-up post-implant there was no detection of sustained 
ventricular tachyarrhythmias. 
3.1 Cardiac resynchronization therapy 
Cardiac resynchronization therapy was associated with improved functionality with New 
York Heart Association classification, from 3,0±0,2 to 2,1±0,5, ρ<0.05 (Figure 3). 
 
12.8%
4.0%
72.3%
94.0%
14.9%
2.0%
0.0%
20.0%
40.0%
60.0%
80.0%
100.0%
Class I Class II Class III Class IV
Previous
6th Month
 
 
Fig. 3. Functionality at 6th Month Follow-up in Cardiac Resynchronization Therapy 
This therapy improved left ventricular ejection fraction, from 24,6±6,4% to 35,5±11,9%, 
ρ<0.05 (Figure 4). 
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Fig. 4. Left Ventricular Ejection Fraction (LVEF) at 6th Month Follow-up in Cardiac 
Resynchronization Therapy 
Cardiac resynchronization therapy improved quality of life in the various fields and sums 
assessed except for the self-efficacy domain, high before this therapy (from 81,6±28,9 to 
88,1±24,1, non significant): physical limitation domain from 52,3±26,7  to 83,1±23,6; symptoms 
domain from 55,6±27,6 to 80,1±22,3; quality of life domain from 37,4±30,1 to 75,9±28,6; social 
interference domain from 57,8±30,9 to 84,6±25,9; functional status sum from 55,7±25,6 to 
82,7±20,7 and clinical summary sum from 53,1±25,7 to 81,1±22,1,ρ<0.05 (Figure 5).  
 
 
Fig. 5. Quality of Life at 6th Month Follow-up in Cardiac Resynchronization Therapy  
We have stratified some of these patients regarding the type of therapeutic response: thirty 
four patients responded to this therapeutic and nine did not respond to cardiac 
resynchronization therapy.  
Fifteen patients have a left ventricular ejection fraction superior to 45% post cardiac 
resynchronization therapy and were classified as super-responders, nineteen patients have a 
sustained improvement in functional class and an increase in left ventricular ejection 
fraction of 15% and were classified as responders and nine patients have no clinical or left 
ventricular ejection fraction improvement and were classified as non-responders. 
The age and the etiology was identical (65,1±8,2 years between 48-75 years, 63,2±11,1 years 
between 37-78 and 62,8±6,1 years between 55-71 years for super-responders, responders e 
non-responders respectively and etiology mainly idiopathic with the majority of the cases 
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followed by ischemic etiology according to the results described for the whole group 
submitted to cardiac resynchronization therapy) but the gender was different with super-
responders being in majority women (53,3% female and 46,7% male) and responders and 
non responders being in majority men (84,2% male and 15,8% female and 77,8% men and 
22,2% female for responders and non-responders respectively). 
Super-responders had a left ventricular ejection fraction prior to cardiac resynchronization 
therapy average superior to 25% (29,5±4,5) while responders and non responders presented 
a left ventricular ejection fraction prior to cardiac resynchronization therapy average inferior 
to 25% (22,6±6,2 and 23,9±6,5) (Figure 6). 
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Fig. 6. Left Ventricular Ejection Fraction Regarding the Type of Therapeutic Response 
Super responders and responder had the all of their patients in class III of the New York 
Heart Association classification prior to therapy while non-responders despite having the 
majority of the patients in class III (66,7%) also had patients in class II (22,2%) and class IV 
(11,1%) of the New York Heart Association classification prior to therapy (Figure 7). 
Non responders presented a low quality of life before this therapy and have not perceived 
any improvement on their quality of life (physical limitation domain from 25,2±21,9  to 
59,1±37,4; symptoms domain from 46,5±33,3 to 63,6±28,2;  self-efficacy domain from 95,8±7,3 
to 97,59±7,1; quality of life domain from 20,8±27,4 to 52,1±35,1; social interference domain 
from 37,5±31,5 to 63,8±36,8; functional status sum from 38,1±28,9 to 63,8±30,4 and clinical 
summary sum from 34,8±28,4 to 60,1±32,2) (Figure 8). 
Super-responders and responders started with a better perception of their quality of life  and 
identify improvement in quality of life in all dimensions and sums,p≤0,05 except for the 
auto-efficacy dimension in responders where there was no statistical significant change 
(physical limitation domain from 51,8±24,6  to 90,4,1±13,7; symptoms domain from 53,9±27,6 
to 84,5±21,8;  self-efficacy domain from 76,2±34,3 to 95,7±11,6; quality of life domain from 
38,7±31,6 to 85,1±24,5; social interference domain from 55,8±27,1 to 85,7±28,9; functional 
status sum from 55,3±22,6 to 87,7±17,4 and clinical summary sum from 52,6±23,4 to 
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60,1±32,2 for super responders and physical limitation domain from 63,1±23,7  to 89,1±15,3; 
symptoms domain from 60,1±25,7 to 82,4±20,9; self-efficacy domain from 76,9±33,1 to 
83,3±26,8; quality of life domain from 39,8±27,4 to 75,1±27,6; social interference domain from 
63,9±31,7 to 90,2±18,3; functional status sum from 62,6±23,8 to 86,6±15,7 and clinical 
summary sum from 59,2±23,7 to 84,9±17,8 for responders) (Figure 9 and Figure 10).  
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Fig. 7. New York Heart Association Classification Regarding the Type of Therapeutic 
Response 
 
 
Fig. 8. Quality of Life in Non-responders 
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Fig. 9. Quality of Life in Super-responders 
 
 
Fig. 10. Quality of Life in Responders 
3.2 Implantable cardioverter-defibrillator  
Implantable cardioverter defibrillator was associated with improved functionality with New 
York Heart Association classification from 2,1±0,3 to 1,9±0,5 ρ<0.05 (Figure 11). 
 
 
Fig. 11. Functionality at 6th Month Follow-up in Implantable Cardioverter Defibrillator 
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This device was not associated with improvement in left ventricular ejection fraction (from 
26,1±5,4 to 26,4±5,9), where changes were no significant (Figure 12).  
 
 
Fig. 12. Left Ventricular Ejection Fraction (LVEF) at 6th Month Follow-up in Implantable 
Cardioverter Defibrillator 
Implantable cardioverter-defibrillator improved quality of life only in social interference 
domain from 73,9±34,4 to 82,7±27,5, quality of life domain from 54,3±32,1 to 71,1±28,1 and 
clinical summary sum from 72,4±24,1 to 78,4±25,1,ρ<0.05. In the physical limitation domain 
(from 76,2±24,5 to 80,4±26,1), symptoms domain (from 73,6±24,7 to 78,1±24,6), self-efficacy 
domain (from 80,3±26,2 to 83,6±25,1) and functional status sum (from 76,2±23,1 to 
80,4±23,9), changes were no significant (Figure 13). Initial scores in every dimension and 
sum were high before the implantation of this device. 
 
 
Fig. 13. Quality of Life at 6th Month Follow-up in Implantable Cardioverter Defibrillator 
4. Discussion 
In this study the cardiac resynchronization therapy combined with implantable 
cardioverter-defibrillator improved left ventricular function, functionality and quality of life 
at six months follow-up.  According to the European Cardiac Society, 2008 the survival 
advantage of cardiac resynchronization therapy with implantable cardioverter-defibrillator 
has not been adequately addressed. However due to the documented effectiveness of  
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implantable cardioverter-defibrillator therapy in the prevention of sudden cardiac death, the 
use of cardiac resynchronization therapy associated to implantable cardioverter-defibrillator 
is commonly preferred in clinical practice in patients satisfying cardiac resynchronization 
therapy criteria including an expectation of survival with good functional status for more 
than one year. Lousano et al., 2005 in the VENTAK CHF/CONTAK CD study followed 490 
heart failure patients with indication for an implantable cardioverter-defibrillator compared 
antitachycardia pacing efficacy in patients with or without cardiac resynchronization 
therapy. These authors encountered that the efficacy of biventricular antitachycardia pacing 
in heart failure patients is significantly better in those with cardiac resynchronization 
therapy than in those without.  
Other studies have identified the benefits of this therapy in mortality and morbidity of 
patients with heart failure. Bristow et al., 2004 in the COMPANION study analysed the 
effect of the cardiac resynchronization therapy in mortality and hospitalization among 
patients with advanced chronic heart failure and intraventricular conduction delays. 
1520 patients in New York Heart Association class III or IV due to ischemic or non-
ischemic cardiomyopathies and a QRS interval of at least 120 ms were randomly 
assigned in three groups to receive optimal pharmacologic therapy (diuretics, 
angiotensin-converting–enzyme inhibitors, beta-blockers and spironolactone) alone or in 
combination with cardiac resynchronization therapy with either a pacemaker or a 
pacemaker–defibrillator. These authors encountered that cardiac resynchronization 
therapy decreases the combined risk of death from any cause or first hospitalization and, 
when combined with an implantable defibrillator, significantly reduces mortality. 
Cleland et al., 2005 in the CARE-HF study analyzed the effects of cardiac 
resynchronization therapy on morbidity and mortality among patients with heart failure 
due to left ventricular systolic dysfunction and cardiac dyssynchrony. 813 patients with 
New York Heart Association class III or IV heart failure due to left ventricular systolic 
dysfunction and cardiac dyssynchrony who were receiving standard pharmacologic 
therapy were randomly assigned to receive medical therapy alone or with cardiac 
resynchronization. These authors encountered that cardiac resynchronization increases 
left ventricular ejection fraction, improve symptoms and the quality of life and reduce 
complications and the risk of death. McAlister et al., 2007 in a systematic review 
concerning the efficacy, effectiveness and safety of cardiac resynchronization therapy in 
patients with left ventricular systolic dysfunction in a total of 14 randomized trials 
involving 4420 patients, observed that cardiac resynchronization therapy improved left 
ventricular ejection fraction, quality of life and functionality and decreased 
hospitalizations and all cause mortality with a high implant rate and low lead problems 
during eleven months follow-up. They conclude that this therapy reduces morbidity and 
mortality in patients with left ventricular systolic dysfunction, prolonged QRS duration 
and New York Heart Association class III and IV symptoms when combined with 
optimal pharmacotherapy. About the sustained effect of this therapy Sutton et al., 2006 
in the MIRACLE study followed 228 patients submitted to cardiac resynchronization 
therapy during twelve months post-implantation to determine whether reverse left 
ventricular remodeling and symptomatic benefit from this therapy were sustained at one 
year and if so, in what proportion. These authors encountered that reverse left 
ventricular remodeling and symptom benefit are sustained at twelve months in patients 
with New York Heart Association  class III/IV heart failure but occur to a lesser degree 
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in patients with ischemic versus non-ischemic etiology, according to them most likely 
owing to the inexorable progression of ischemic disease. 
Despite the good results achieved with cardiac resynchronization therapy according to 
Santos et al., 2006 one third of the patients do not benefit from it. In our study, from 
forty-three patients, eight did not respond to this therapy. This group identified a low 
quality of live before implantation and did not perceive any improvement after cardiac 
resynchronization therapy. Also in this non-responding group we had patients in class II 
to IV of the New York Heart Association classification before intervention. Interestingly 
the super-responders were majority women and have a left ventricular ejection fraction 
prior to implantation superior to 25%. The response to this therapy was associated to 
improvement of quality of life perceived by the patients and a New York Heart 
Association class III classification before implantation. There are few studies regarding 
the predictors of response to this therapy. Quiao et al., 2011 in a study with seventy-six 
consecutive patients submitted to cardiac resynchronization therapy divided in to super-
responders, responders and non-responders conclude that patients with a smaller left 
ventricle would have a better chance to become super-responders. Santos et al., 2006 in 
twenty-three consecutive patients with heart failure refractory to medical therapy who 
underwent cardiac resynchronization therapy studied regarding the type of response 
before and six months after the procedure evaluating clinical, electrocardiographic and 
echocardiography characteristics concluded that left ventricular dyssynchrony can be 
quantified by tissue Doppler imaging using QS (max-min) and values greater than 60 ms 
can identify responders to this therapy. This actual field under investigation requires 
more studies to determine the reasons for a percentage of these patients do not  
respond to cardiac resynchronization therapy including personal characteristics of the 
patients. 
In this study implantable cardioverter-defibrillator alone was associated with 
improvement of functionality and quality of life already high in baseline due to the 
majority of the patients being in class II of the New York Heart Association classification. 
When looking to the various dimensions concerning the quality of life we stated that this 
improvement is observed in social and quality of life domains with this patients referring 
improvement of the perception of their enjoyment of life and of their sense of 
discouragement due to their heart failure and how congestive heart failure affects the 
patient’s lifestyle at six month follow-up, emphasizing the necessity of looking to all 
dimensions evaluated in quality of life and not only the overall score to characterize the 
evolution of patients to clinical interventions. It is known the effect of this device on 
improving survival, however remains unclear the effect of this treatment in quality of life. 
Bardy et al., 2005 in the SCD-HeFT study concerning the effect of amiodarone or a 
conservatively programmed, shock-only implantable cardioverter-defibrillator in 
reducing the risk of death in patients with mild-to-moderate congestive heart failure, 
followed 2521 patients in class II or III with chronic stable heart failure due to ischemic or 
non-ischemic causes and left ventricular ejection fraction ≤35% randomized for receiving 
amiodarone, implantable cardioverter-defibrillator or placebo. These authors encountered 
that in patients with mild-to-moderate congestive heart failure, conservatively 
programmed, shock-only implantable cardioverter-defibrillator significantly reduces risk 
of death while amiodarone shown no benefit compared with placebo; implantable 
cardioverter-defibrillator therapy had significant benefit in patients with New York Heart 
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Association class II but no significant effect in patients with class III; amiodarone had no 
benefit in patients with New York Heart Association class II  and showed a significant 
reduction in survival in patients with class III compared to placebo.  Noyes et al., 2009 in 
the MADIT-II study followed 938 patients randomized to receive an implantable 
cardioverter-defibrillator or medical therapy alone during thirty six months. These 
authors encountered that development of congestive heart failure and shocks among 
patients and their negative effect on quality of life may partially explain the lack of quality 
of life benefit from this therapy. Probst et al., 2011 have studied the psychological impact 
of implantable cardioverter-defibrillator on Brugada syndrome patients. 190 patients were 
divided in three groups: symptomatic implanted patients, asymptomatic implanted 
patients and asymptomatic patients without implantable cardioverter-defibrillator and 
were evaluated regarding the quality of life.  These authors concluded that whatever the 
group, Brugada patients have a good quality of life with no difference between implanted 
and non-implanted patients. Despites the difficulties in their social and professional life 
regarding the tolerance of this device, patients considered implantation of cardioverter-
defibrillator reassuring.  
5. Conclusion 
In a selected population with severe chronic heart failure, cardiac resynchronization therapy 
was associated with improvement in all domains of quality of life, functional class and left 
ventricular function. Regarding the type of response to this therapy, patients with positive 
clinical response and reverse remodeling, obtained a favorable impact in all dimensions of 
quality of life, while the group without response showed no improvement, with some 
differences between the responding and the non-responding patients like gender, perceived 
quality of life and the New York Heart association classification prior to implantation of the 
device that needs further investigation. 
Implantable cardioverter-defibrillator benefits were restricted to the social dimension of 
quality of life and perception of life satisfaction, indicating that this intervention as no 
unfavorable impact in quality of life in the first six months after the implantation of this 
device in patients without detection of sustained ventricular tachyarrhythmias 
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